Healthcare Social Media and Updates
Healthcare Social Media and Updates
Healthcare Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Onboarding your team or clinic to a new AI tool is so important, but often difficult. At Glass, we've made it incredibly easy — you can now get your whole clinic set up in a few minutes.
🚨Computation Without Consequence 👉A clinical study reveals the divide between AI computation and human judgment. 📌AI handles patterns with ease. 📌Humans feel the weight of being wrong. 📌That’s where the divide becomes clear and important. https://t.co/tjfOTsWnCC #AI #medicine #digitalhealth
A systematic RCT analysis of GLP-1 drugs show they are more effective in women than men for weight loss https://t.co/cycwi4nnN5 https://t.co/KOl0FgKaZD
Roche pill succeeds in another MS study, but approval questions linger https://t.co/JY8uZCI5iA @ByJonGardner $RHHBY $SNY
UniQure says FDA wants another study of Huntington’s gene therapy https://t.co/1pgFDoE2V9 by @realJacobBell $QURE - 35% #GeneTherapy #Huntingtonsdisease
I taught my medical students about every risk factor for early death — smoking, obesity, diabetes, hypertension. I never once mentioned optimism. A PNAS study of two large epidemiologic cohorts found that the most optimistic people lived 11–15% longer on average —...
I'm excited to announce something new. After 30 years of teaching at UCLA and USC, I've started a newsletter called Health Longevity Secrets. Every week: what medical school gets wrong, how to read your labs, evidence-based longevity strategies. Free: http://robertlufkinmd.substack.com
AI of whole slide images for cancer molecular markers is not ready for clinical use due to confounding and biases ("shortcut learning"), supported by multiple examples @natBME https://t.co/zG8uVIxrJf https://t.co/hQ0tjiapIJ
A new mechanism for improved cognitive function from exercise in the Alzheimer's disease model Skeletal muscle EC vesicles interact with the brain and rev up microglia function https://t.co/eZu14YVasY
I keep seeing AI-pilled people arguing that AI agents will magically solve patient engagement - but it won’t. If it were that easy, non-Tech solutions would’ve solved it already. At @SeamlessMD, I’ve spent the last 13+ years working with health systems...
System consolidation looks efficient—until you count the cost of disruption. Strong view from @Provationmed on why migrating away from purpose-built clinical documentation puts adoption, revenue, and trust at risk. ➡️ https://t.co/WahjLaV8Wl #ClinDoc #CIOInsights #HITSM
Safety concerns spur Aardvark to halt key Prader-Willi drug trial https://t.co/PWkOuDMIvo $AARD - 52% $SLNO
Stanley Plotkin, known as the “godfather of vaccines,” in an interview with @HelenBranswell: “All I can say is that I’m beginning to regret having lived so long — because we’re going downhill.” https://t.co/A2zcoP2Ghd
New @NatureMedicine A randomized trial of antibody vs activin type II receptors with or without semaglutide (Ozempic). The antibody, bimagrumab, promotes muscle growth. Marked weight loss with the combination https://t.co/XUK93GTAmA
Stanley Plotkin had a major hand in the development of a number of vaccines in use today; he designed the rubella vaccine. He remembers the world before widespread use of vaccines & knows what's coming as vaccine policy is rewritten...
Someday we'll be able to track our immune system like we do glucose Today @NatBME https://t.co/HFcFiUeyFg Previously @ScienceMagazine https://t.co/EcgBdwGxcd https://t.co/SpoZ5bLtjx
I used to teach that osteoarthritis was "wear and tear" — lose weight, take painkillers, wait for a knee replacement. A study just published in Cell Metabolism proved that wrong. Semaglutide (Ozempic) didn't just reduce joint pain in osteoarthritis patients — it...
Who's heard of Flare Therapeutics? #GU26 late-breaker shows promise in hitting "undruggable" PPAR-γ target, with a few major caveats. Via @ApexOnco -> https://t.co/1GepvywtL0
“Nobody wants to feel cornered:" Europe braces for the fallout of Trump's drug pricing plan https://t.co/HZjZH0mdCU
The Duchenne muscular dystrophy patient & advocacy community keeps a gene therapy and multiple drugs on the US market, stopping the FDA from taking action, despite failed confirmatory clinical trials showing no efficacy and questionable safety. The Huntington's disease patient and...
$NTLA drug is off hold but now being restricted by the FDA to the least severe/sick patients, which would logically be those least likely to want/need an experimental gene editing therapy. Existing options will dominate. Target/disease selection is a...
$MRK claims a survival benefit in ovarian cancer irrespective of PD-L1 status, but FDA & EMA say BS. Via @ApexOnco -> https://t.co/Cld1O7Uuvp #ESGO26
$QURE AMT-130 update: Still blocked The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for...
But also it’s not only measles, pertussis (whooping cough) is also returning, and based on latest ACIP (or what used to be ACIP) stunts, we’ll see rotavirus, meningococcal meningitis, HBV liver cancer, return after that. A public health disaster built...
According to ITOA, NAD declines with age, causing epigenetic changes & disease susceptibility In 2010, we showed NAD-dependent enzyme, SIRT3, protects the heart 🐁 New study says NAD precursor NMN protects the heart via SIRT3 in mice fed a Western diet https://www.sciencedirect.com/science/article/pii/S0022316626000842
Checking out the humanoid robots with Jason Fung at the Tesla Diner as we celebrate the release of his remarkable new book, The Hunger Code—a bold rethinking of obesity and weight loss. The Hunger Code is poised to help thousands lose...
I never once mentioned microplastics in 20 years of teaching at medical school. Now they've been found inside human brains — and at significantly higher concentrations in people with dementia. A Frontiers in Neurology review lays out the damage: Microplastics cross the...
Primary care receives only five cents of every health care dollar [PODCAST] http://dlvr.it/TRD584 Podcast #PrimaryCare
$MRK Welireg could be about to expand its reach at last. #GU26 data via @ApexOnco with relevance to $RCUS -> https://t.co/k59284INdK
Complete Metabolic Heart Scan * CT Coronary Artery Calcium Score� * CT Calculated Arterial Age� * CT Liver Fat Quantification� * CT Bone Mineral Density� (available anywhere in the US) https://www.innerscopic.com/
How is it that a paper that claims to show how to do target trial emulation does not address confounding by indication and its ramifications for data collection? https://t.co/dzGZZdpBoc #Statistics
Some very good news about engineering our cells vs cancer (accelerating the CAR). A short thread 1. For background, a new 5★ review on cancer immunotherapy @Cancer_Cell https://t.co/1Qz2rCs8I5 https://t.co/sJ6BwaXyjk
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma https://t.co/5t0M2eX0fB https://t.co/p3kv8LEzrC
There are a few known chemical exposures in early pregnancy that interact with autism genes. But not Tylenol. I’ve spoken to RFK Jr about them but he had no interest, and he can’t process scientific information. Here’s my article https://t.co/pxLaDLInlf
Reye’s syndrome is a well known condition that causes life-threatening cerebral swelling in children infected w/ certain viruses like chickenpox or Flu; it’s associated w/ treating the fever w/ aspirin. Prenatal cases are extremely rare. Baby aspirin is used in...
A leader of this next wave of AI-focused biotechs has completed its IPO, a milestone tarnished by a brutal first few hours of trading. Day 1 for $GENB: -23% https://t.co/u3WQcDD3jL
"Smart” doesn’t mean distant. The smartest hospital ecosystems actually bring clinicians closer to patients by reducing administrative burden. Insights from Jeff Fallon at eVideon: https://t.co/x7o1COnGIe @eVideon @TigerConnect #SmartHospitals #HITsm https://t.co/PVVG70mbKN
An intriguing tale of three cities. How do the PD1xCTLA4 bispecific agents lorigerlimab, volrustomig, and cadonilimab stack up when it comes to design and performance? Some useful and pointed lessons here for biotech execs: https://t.co/xaSW15Fvdl https://t.co/dhXbiI3N6v
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA https://t.co/xLp2oQDHGy $RNA $NVS #startups
“The era of de novo proteins is coming a lot faster than probably people recognize,” Generate's CEO Mike Nally tells me. “I think within the next year or two you’ll start seeing de novo designs enter the clinic.” https://t.co/u3WQcDD3jL
Hospitals aren’t asking IF they need virtual care anymore — they’re asking how deeply it integrates. Insightful take from @_artisight's Jay Lyonett at #ViVE2026. 👉 https://t.co/ckEzNYH8oS
An important study just came out that is the first to evaluate patient safety when it comes to ChatGPT Health. Millions of people are using LLMs every week to triage health conditions, but this new study has found concerning inconsistencies. https://t.co/etjthA2olM
AI is helping to make the diagnosis of rare diseases. A new multicenter study in Japan showed smartphone AI diagnosis of acromegaly via hands was better than experienced endocrinologists https://t.co/qBiazetToV https://t.co/dSZpJ2us84
I used to teach that "aging is just wear-and-tear." A new Nature paper used 7 days of wrist-wearable data from ~62,000 adults and found your circadian rhythm patterns (amplitude + stability) and MVPA predict inflammation-linked biological aging. Low rhythm amplitude and poor...
Former surgeon general: The Senate must not approve an SG who can’t practice medicine https://t.co/TfgRw59xFd
Here's the link to watch yesterday's webinar on venture capital, a companion to this year's top 100 biotech VCs list with @ChrisDoko Lots of positive feedback here. Post your thoughts. https://t.co/c16y04mFsD
Elizabeth Cairns' piece on $Novo is reminiscent of Bristol Myers' strategic fail against Merck and Keytruda. They were focused on the wrong things, made bad trial design decisions and got stuck in the mud of their own making. Everyone should...
How does obesity catalyze neurodegeneration? Our paper just out @NatMetabolism https://t.co/kx25urgpJx free access https://t.co/aL1FBN9MyI Phenomenal work by @chen_bandy pulling this together
“You can’t stand there after the fact and blame the open-label design,” he said. “You designed it. You designed a noninferiority margin. You picked the patients. And then the trial doesn’t work.” https://t.co/acS5i5s5NU
Great to see our former National School of Tropical Medicine @BCM_TropMed trainee Dr. Leroy Versteeg at my Brown Molecular Medicine talk at @UTHealthHouston in our @TXMedCenter https://t.co/F9IGkVNkfM
